The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1291
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Duloxetine (Cymbalta) for Fibromyalgia

Duloxetine (Cymbalta– Lilly) is the second drug to be approved by the FDA for treatment of fibromyalgia. Pregabalin (Lyrica), which is also approved for treatment of neuropathic pain and epilepsy, was the first.1 Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that is already marketed for treatment of depression and diabetic neuropathy.2,3

FIBROMYALGIA — A chronic disorder mainly affecting women, fibromyalgia is characterized by diffuse musculoskeletal pain and is often associated with fatigue, irritable bowel symptoms and sleep problems. It has been treated with many different drugs, including analgesics, muscle relaxants, anticonvulsants, and antidepressants, particularly the tricyclic antidepressant amitriptyline (Elavil, and others). Non-drug treatments such as exercise and cognitive behavioral therapy have also ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1291
 Downloadable, electronic issue - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian